Morgan Stanley downgraded shares of T2 Biosystems Inc (NDAQ:TTOO) from an equal weight rating to an underweight rating in a report published on Wednesday, StockTargetPrices.com reports.
T2 Biosystems (NDAQ:TTOO) traded down 1.65% during midday trading on Wednesday, hitting $5.96. 6,338 shares of the stock were exchanged. The company has a 50 day moving average price of $5.81 and a 200 day moving average price of $6.09. The firm’s market capitalization is $181.67 million. T2 Biosystems has a one year low of $4.89 and a one year high of $11.30.
Your IP Address:
T2 Biosystems Company Profile
T2 Biosystems, Inc is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company’s T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL).
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/t2-biosystems-inc-ttoo-cut-to-underweight-at-morgan-stanley/1709131.html
Receive News & Ratings for T2 Biosystems Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems Inc and related companies with MarketBeat.com's FREE daily email newsletter.